186,272 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Bought by Parkman Healthcare Partners LLC

Parkman Healthcare Partners LLC acquired a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) in the fourth quarter, Holdings Channel reports. The institutional investor acquired 186,272 shares of the biopharmaceutical company’s stock, valued at approximately $13,341,000. Intra-Cellular Therapies comprises about 1.9% of Parkman Healthcare Partners LLC’s portfolio, making the stock its 19th biggest position.

A number of other hedge funds also recently made changes to their positions in the stock. Avoro Capital Advisors LLC acquired a new stake in Intra-Cellular Therapies in the fourth quarter valued at approximately $161,543,000. Lighthouse Investment Partners LLC purchased a new position in Intra-Cellular Therapies during the fourth quarter worth about $4,473,000. Regal Investment Advisors LLC boosted its holdings in shares of Intra-Cellular Therapies by 6.5% in the 4th quarter. Regal Investment Advisors LLC now owns 14,501 shares of the biopharmaceutical company’s stock worth $1,039,000 after purchasing an additional 891 shares in the last quarter. Schroder Investment Management Group lifted its stake in shares of Intra-Cellular Therapies by 36.7% in the 4th quarter. Schroder Investment Management Group now owns 779,823 shares of the biopharmaceutical company’s stock valued at $55,851,000 after acquiring an additional 209,331 shares during the last quarter. Finally, Eagle Asset Management Inc. raised its position in Intra-Cellular Therapies by 5.5% during the 4th quarter. Eagle Asset Management Inc. now owns 435,718 shares of the biopharmaceutical company’s stock valued at $31,206,000 after purchasing an additional 22,628 shares during the last quarter. 92.33% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have commented on the company. Mizuho increased their target price on Intra-Cellular Therapies from $82.00 to $96.00 and gave the company a “buy” rating in a research note on Monday, April 22nd. Needham & Company LLC reissued a “buy” rating and set a $90.00 price objective on shares of Intra-Cellular Therapies in a research note on Tuesday, May 7th. Royal Bank of Canada reiterated an “outperform” rating and issued a $86.00 price target on shares of Intra-Cellular Therapies in a report on Wednesday, April 3rd. Robert W. Baird upped their target price on Intra-Cellular Therapies from $83.00 to $103.00 and gave the stock an “outperform” rating in a report on Wednesday, April 17th. Finally, Bank of America upped their target price on Intra-Cellular Therapies from $82.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, April 17th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $91.50.

Intra-Cellular Therapies Stock Performance

Shares of ITCI stock traded up $0.21 during trading on Thursday, hitting $68.41. 701,402 shares of the company were exchanged, compared to its average volume of 885,480. The firm has a market capitalization of $7.22 billion, a price-to-earnings ratio of -58.43 and a beta of 0.97. Intra-Cellular Therapies, Inc. has a twelve month low of $45.50 and a twelve month high of $84.89. The business’s 50-day simple moving average is $68.83 and its 200 day simple moving average is $68.12.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.15. Intra-Cellular Therapies had a negative net margin of 21.57% and a negative return on equity of 18.49%. The business had revenue of $144.90 million for the quarter, compared to the consensus estimate of $141.41 million. During the same period last year, the company posted ($0.46) EPS. Intra-Cellular Therapies’s revenue for the quarter was up 52.0% on a year-over-year basis. On average, equities analysts forecast that Intra-Cellular Therapies, Inc. will post -0.53 earnings per share for the current fiscal year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.